This article first appeared on GuruFocus .
Release Date: March 26, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Innate Pharma SA ( NASDAQ:IPHA ) has received FDA clearance to proceed with the Telemax 3 phase 3 trial for lacutamab in CTCL, with initiation expected in the second half of 2026.
-
IPH 4,502 is showing early signs of anti-tumor activity in heavily pretreated patients, including those with urothelial cancer, and has a favorable safety profile.
-
Monalizumab, in partnership with AstraZeneca, is progressing with the Pacific 9 phase 3 trial data readout expected in the second half of 2026.
-
The company has streamlined its organization to support efficient decision-making and disciplined capital allocation.
-
Innate Pharma SA ( NASDAQ:IPHA ) has a cash position of 44.8 million, providing funding visibility until the end of the third quarter of 2026.
Negative Points
-
Operating expenses were 63 million, with a significant portion related to R&D, reflecting high costs associated with ongoing studies.
-
Revenue and other income amounted to only 9 million, indicating limited income generation from current operations.
-
The company is still in the process of evaluating financing options for the phase 3 study of lacutamab, indicating potential funding challenges.
-
The collaboration revenue from the monalizumab program has dropped significantly, reflecting a shift in project management to AstraZeneca.
-
There is a significant therapeutic gap in the post-EV setting for urothelial cancer, highlighting unmet needs that IPH 4,502 aims to address.
Q & A Highlights
Q: Can you provide additional specifics regarding the IPH 4,502 program and how it stands against competitors in the nectin 4 ADC space? A: Jonathan Dickinson, CEO: We are very excited about the IPH 4,502 program. The study is progressing well with significant interest. Recent competitive developments reinforce our positioning. As a Topo1 ADC, IPH 4,502 has a unique opportunity in the post-PAD setting, which was not available to MMAE-based ADCs. Sonia Quaratino, CMO: We have established the maximum tolerated dose and are encouraged by preliminary activity at therapeutic doses across different tumor types.
Q: Regarding the Matisse interim data presentation at AACR, what should we expect from the program? A: Yannis Morell, COO: The Matisse trial, in collaboration with AstraZeneca, aims to generate sufficient data to validate the target and explore development in lung cancer. The interim analysis will cover the first 40 patients, with the trial continuing to include up to 70 patients. The data will be presented at AACR, focusing on efficacy.
Q: With the collaboration revenue from the monalizumab program dropping, do you foresee any additional milestones, especially with the upcoming Pacific 9 readout? A: Frederic Lombard, CFO: The revenue drop relates to the old agreement. The project is now entirely in AstraZeneca's hands, with accounting treatment differing. Future development will depend on upcoming results expected in the second half of the year.
Q: Can you provide updates on partnership discussions for Lacutamab and potential deal structures? A: Jonathan Dickinson, CEO: Our priority is to get Lacutamab to market quickly. Timelines for approval look similar for both BD options and royalty financing. We will run the phase 3 studies, controlling timelines and regulatory interactions. Our decision will focus on long-term shareholder value, evaluating both BD partnerships and royalty financing structures.
Q: What can we expect from the upcoming data readouts for the ADC, and what sales infrastructure are you planning for Lacutamab? A: Sonia Quaratino, CMO: We aim to present a comprehensive safety profile, PK data, and efficacy readouts, including nectin 4 expression in tumors. Jonathan Dickinson, CEO: For sales infrastructure, if we proceed independently, a small team will suffice due to the concentrated treatment landscape in the US, requiring around 20 salespeople, 5-6 medical affairs staff, and a few access personnel.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
